Biotech Values

[daved]

MCU has an SPA that seems to match exactly those criteria in the P2 that show high statistical significance. Buy it at 1.16 now or wait for P3 data release early next year and buy it for 3.5.

First we should call the company and try to verify exactly how MI will be measured and how that corresponds to the data from P2. Trying to raise 20 mil for the P3 trial they actually raised 25 mil. Some institutions believe.

This drug is designed to give the patient a healthier heart post-op. Reducing deaths in the first 30 days post surgery would be nice too but unnecessary for stat sig.

Aggrastat sales topped 1 mil in December with a new sales force. It averaged 750K last year with noone selling it. It tops 3 mil in the EU every month. So far we don't know what constitutes breakeven here in the US. The jury is out.

The positive or negative prospects for MCI far outweigh any plus or minus that Aggrastat will have on share price.

Dave